Poster Session B
Sunday, Sept. 15, 2019
12:30-3:30 p.m.

B01 Optimizing chemotherapy for the integration of immune therapy in ovarian cancer: Enriching effector T-cells in the peritoneal tumor microenvironment using the route of cisplatin administration (IV vs. IP). Henning De May, University of New Mexico School of Medicine, Albuquerque, NM, USA.

B02 miR-181a initiates and perpetuates oncogenic transformation through the regulation of innate immune signaling. Analisa Difeo, University of Michigan, Ann Arbor, MI, USA.

B03 Immunotherapy of ovarian cancer with glycomimetic peptides. J. Kenneth Hoober, Susavion Biociences, Inc., Tempe, AZ, USA.

B04 Immune modeling analysis identifies ICOS and CTLA-4 as predictive biomarkers in serous epithelial ovarian cancer. Nicole James, Women and Infants Hospital, Providence, RI, USA.

B05 Induction of DNA damage in high-grade serous carcinoma induces type I interferon signaling. Karen McLean, University of Michigan, Ann Arbor, MI, USA.

B06, PR09 An unexpectedly effective immunotherapy strategy for ovarian cancer. Jogender Tushir-Singh, University of Virginia, Charlottesville, VA, USA.

B07 Ovarian cancer stem like cells and alternately activated macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments. Geeta Mehta, University of Michigan, Ann Arbor, MI, USA.

B08, PR05 Patient-derived tumoroids for exploration of the ovarian cancer stem cell regulation, chemoresistance, and tumor heterogeneity. Geeta Mehta, University of Michigan, Ann Arbor, MI, USA.


B10, PR06 Dissecting mechanisms of replication fork stabilization in patient-derived high-grade serous organoid cultures and their impact on therapeutic sensitivity and the immune-tumor interaction. Sarah Hill, Dana-Farber Cancer Institute, Boston, MA, USA.

B11 Collective extrusion initiates dissemination in organotypic model of high-grade serous carcinoma. Marcin Iwanicki, Stevens Institute of Technology, Hoboken, NJ, USA.
Poster Session B
Sunday, Sept. 15, 2019
12:30-3:30 p.m.

B12 3D perfusion bioreactor system as a model for studying cell biology of Ovarian Cancer. Alba Martinez, University of Alabama at Birmingham, Birmingham, AL, USA.

B14 Atovaquone targets STAT3 in ovarian cancer spheroids. Kayli Neil, University of New Hampshire, Durham, NH, USA.

B15 BRCA haploinsufficiency promotes gluconeogenesis in fallopian tube epithelial cells. Iru Paudel, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA.

B16 STAT3 promotes ovarian cancer spheroid growth and metastasis. David Walker, University of New Hampshire, Durham, NH, USA.

B17 Modeling ovarian cancer in mice using in vivo electroporation and CRISPR-mediated genome editing. Yojiro Yamanaka, McGill University Goodman Cancer Research Centre, Montreal, QC, Canada.

B18 Transcriptional profiling of tumor stroma using ovarian cancer PDX models with induced platinum-resistance. Valentina Zanfagnin, Mayo Clinic, Rochester, MN, USA.

B19, PR12 Genetic aberrations dictate distinct tumor immune landscape and chemosensitivity in HGSOC. Shuang Zhang, Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA.


B21 Oncogenic BRAF and KRAS mutations in endosalpingiosis. M. Herman Chui, Johns Hopkins Medical Institutions, Baltimore, MD, USA.

B22 Development of the first ovarian carcinosarcoma patient derived xenograft and tissue organoid model to predict clinical response to chemotherapy. Justin Gorski, University of Kentucky, Lexington, KY, USA.
Poster Session B
Sunday, Sept. 15, 2019
12:30-3:30 p.m.

B23 CDK4/6 and MEK inhibitor combination in low-grade serous ovarian cancer cell lines. Joshua Hoenisch, University of British Columbia, Vancouver, BC, Canada.

B24, PR11 Dual blockade of BRD4 and the ATR/WEE1 pathway exploits ARID1A loss in clear cell ovarian cancers. Yasuto Kinose, Penn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

B25 SMARCA4/BRG1 and AP-1 co-regulate an epithelial-like signature in small cell carcinoma of ovary, hypercalcemic type (SCCOHT). Krystal Orlando, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

B26 The natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions. Tang-Yuan Chu, Buddhist Tzu Chi General Hospital, Hualien, Taiwan, Republic of China.

B27 Cellular retinoic acid binding protein 2 (CRABP2) is a novel biomarker and potential therapeutic target for high-grade serous ovarian carcinomas. Daniele Chaves-Moreira, University of Pennsylvania, Philadelphia, PA, USA.

B28 Optimizing DNA processing and ovarian cancer methylation-specific PCR assays for the detection of early-stage ovarian cancer. Caroline Ford, UNSW Sydney, Sydney, NSW, Australia.

B29 Ovarian hormones regulate C/EBPD induced EMT/MET transition in the human fallopian tube epithelia. Sophia George, Miller School of Medicine, University of Miami Sylvester Comprehensive Cancer, Miami, FL, USA.


B31 Endocervical microRNA profiling for detection of ovarian cancer. Alexandra Harris, University of Virginia, Charlottesville, VA, USA.

B32 Are ovarian cancer risk factors different for women with endometriosis? Alice Lee, California State University, Fullerton, Fullerton, CA, USA.

B33 Reproductive factors and risk of ovarian cancer: The Singapore Chinese health study. Ming Lei, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
B34 LINC00886, a risk locus-associated long non-coding RNA, promotes ovarian cancer progression. Koji Nakamura, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.

B35 Dietary flaxseed supplementation in ovarian cancer: Elucidating the molecular actions of its biologically derived active compounds. Purab Pal, Southern Illinois University School of Medicine, Carbondale, IL, USA.

B36 Anti-malarial agent, atovaquone, inhibits cancer cell proliferation by targeting oxidative phosphorylation and is a candidate for chemoprevention and chemotherapy of ovarian cancer. Manish Patankar, University of Wisconsin-Madison, Madison, WI, USA.

B37 Germline mutations in new susceptibility genes for non-high-grade serous ovarian cancer. Marina Pavanello, School of Women’s and Children’s Health, University of New South Wales, Sydney, NSW, Australia.

B38 Use of progestin-only injectable contraceptive is associated with reduced risk of ovarian cancer in the Ovarian Cancer Association Consortium. Minh Tung Phung, University of Michigan School of Public Health, Ann Arbor, MI, USA.

B39 Family history of ovarian cancer and healthcare-seeking behavior: Does having a family history prompt women to seek health care professional advice? Sun Hee Rim, National Center for Chronic Disease and Public Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA.

B40 Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian cancer. Rosa Ana Risques, University of Washington, Seattle, WA, USA.

B41 Racial/ethnic disparities in epithelial ovarian cancer and its risk factors: the Multiethnic Cohort Study. Danja Sarink, University of Hawaii Cancer Center, Honolulu, HI, USA.

B42 Intrauterine device use and ovarian cancer risk. Naoko Sasamoto, Brigham and Women's Hospital, Boston, MA, USA.

B43 A serum protein biomarker signature for the detection of early stages of ovarian cancer. Amy Skubitz, University of Minnesota, Minneapolis, MN, USA.

B44, PR04 Analyses of Pax2 and Pax8 in maintaining oviduct epithelial homeostasis and fertility. Abdulsalam Soofi, University of Michigan, Ann Arbor, Michigan, USA.
B45 Anti-inflammatory actions of DHA via inhibition of the NF-κB pathway. Kara Starkweather, Southern Illinois University School of Medicine, Carbondale, Illinois, USA.

B46 Trends in stage at diagnosis for ovarian, fallopian tube, and serous primary peritoneal cancers, 2004 – 2015. Julie Townsend, Centers for Disease Control and Prevention, Atlanta, GA, USA.

B47 Physical activity and survival following diagnosis with ovarian cancer. Tianyi Wang, Moffitt Cancer Center, Tampa, FL, USA.

B48 Ovarian cancer risk in laying hens is reduced by dietary polyunsaturated fatty acids: implications for soluble E-cadherin, de novo lipogenesis, and mitochondrial metabolism. Chris Weston, Southern Illinois University School of Medicine, Carbondale, IL, USA.

B49 Effects of exercise on ovarian cancer initiation and progression. Yang Yang-Hartwich, Yale School of Medicine, New Haven, CT, USA.

B50 Direct interrogation of the incessant ovulation hypothesis in a high-fidelity mouse model of high-grade serous cancer. Yali Zhai, University of Michigan, Ann Arbor, MI, USA.

B51 Distinct cancer-associated fibroblast states drive clinical outcomes in high-grade serous ovarian cancer and are regulated by TCF21. Laurie Ailles, Princess Margaret Cancer Centre, Toronto, ON, Canada.

B52 Inhibition of ovarian cancer spheroid adhesion using graphene oxide nanomaterials. Samira Azarin, University of Minnesota, Minneapolis, MN, USA.

B53, PR10 High-throughput functional and multi-omic single cell characterization to elucidate ovarian intratumor and microenvironmental heterogeneity. Kristin Beaumont, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

B54 Adipogenic chemokines, body mass index, and ovarian cancer survival. Alicia Beeghly-Fadiel, Vanderbilt University Medical Center, Nashville, TN, USA.

B55 Epigenetic reprogramming of mesenchymal stem cells by ovarian carcinoma to facilitate metastasis. Lan Coffman, University of Pittsburgh, Pittsburgh, PA, USA.
B56 Tissue transglutaminase/Frizzled receptor clusters regulate WNT transcriptional activity in ovarian cancer stem cells. Salvatore Condello, Indiana University School of Medicine, Indianapolis, IN, USA.

B57, PR08 High-grade serous ovarian tumor cells modulate natural killer cells to create an immune-tolerant microenvironment. Wendy Fantl, Stanford University, Stanford, CA, USA.


B59 Rac1 overexpression promotes epithelial to mesenchymal transition in ovarian cancer cells. Martha Grimes, University of New Mexico, Albuquerque, NM, USA.

B60 Pro-HGF and its activator confer a sustained transformation activity in ovulatory follicular fluid. Hsuan-Shun Huang, Buddhist Tzu Chi General Hospital, Hualien, Republic of China.

B61 The genotype of serous carcinomas shapes the tumor microenvironment and modulates responses to targeted and immune checkpoint therapies. Sonia Iyer, Whitehead Institute for Biomedical Research, Cambridge, MA, USA.

B62 Integrating highly multiplexed imaging with multi-omics data to uncover immunological vulnerabilities in high-grade serous ovarian cancer. Miikka Kilkkila, University of Helsinki, Helsinki, Finland.

B63 Lysophosphatidic acid as a mediator of ovarian cancer cell stemness. Yuliya Klymenko, Indiana University School of Medicine, Indianapolis, IN, USA.

B64 Targeting the pH regulators in the tumor microenvironment for ovarian cancer treatment. Arpita Kulshrestha, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA.

B65 Defining the tumor-immune landscape in a mouse model of high-grade serous carcinoma. Kevin McCool, University of Michigan, Ann Arbor, MI, USA.

B66 Paracrine interactions with microenvironmental fibroblasts promote ovarian cancer metastasis through downregulation of miR-4454. Anirban Mitra, Indiana University School of Medicine, Bloomington, IN, USA.
Poster Session B  
Sunday, Sept. 15, 2019  
12:30-3:30 p.m.

B67 Analysis of function and inhibition of PGE2 pathway members MRP4 and EP4 in treatment of ovarian cancer. Jocelyn Reader, University of Maryland School of Medicine, Baltimore, MD, USA.

B68 Characterization of microtentacle phenotype and function in ovarian carcinomas. Jocelyn Reader, University of Maryland, Baltimore, Baltimore, MD, USA.

B69 Gut microbiome attenuates epithelial ovarian cancer growth and sensitivity to cisplatin: New opportunities for ovarian cancer treatments. Ofer Reizes, Cleveland Clinic, Cleveland, OH, USA.

B70 Rac1 as a therapeutic target in ovarian cancer. Melanie Rivera, University of New Mexico, Albuquerque, NM, USA.

B71 Investigating the role of PAX8 in modulating the tumor microenvironment of high-grade serous ovarian cancer. Amrita Salvi, University of Illinois at Chicago, Chicago, IL, USA.

B72 Single-cell analysis of chemotherapy resistance in ovarian cancer. Timothy Starr, University of Minnesota, Minneapolis, MN, USA.

B73 The search for EGFL6 receptor: Implications for tumor angiogenesis. Mana Taki, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B74 Identifying conserved properties of the epithelial-mesenchymal transition in cancer using highly multiplexed single-cell RNA sequencing. Barbara Vanderhyden, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada.

B75, PR07 Reprogramming the tumor microenvironment with losartan to enhance immunotherapy of ovarian cancer. Lei Xu, Massachusetts General Hospital, Boston, MA, USA.

B76 Pyruvate dehydrogenase: A key to epigenetic regulation in CAFs. Sara Zanivan, Cancer Research UK Beatson Institute, Glasgow, United Kingdom.

B77 PORCN inhibition prolongs survival, decreases tumor burden, and alters the immune microenvironment in ovarian cancer. Jaclyn Arquiette, University of Alabama at Birmingham, Birmingham, Alabama, USA.
B78 Improving chemotherapy response of immunologically cold high-grade serous ovarian cancer with loss of PTEN using STING agonist. Noor Shakfa, Queen's University, Kingston, ON, Canada.

B79 Effect of HIPEC on immune microenvironment in epithelial ovary cancer. Arshi Rizwan, All India Institute of Medical Sciences, New-Delhi, India.

B80 Predictive treatment response models for epithelial ovarian cancer: Comparison of 2D, 3D, and in vivo models. Melica Nourmoussavi, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.